NCT01935453View on ClinicalTrials.gov

A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2014

Conditions
MelanomaLiver CancerPancreatic CancerLung Cancer
Interventions
BIOLOGICAL

Recombinant hGM-CSF Herpes Simplex Virus Injection

Trial Locations (2)

100038

Beijing Shijitan Hospital,CMU, Beijing

200032

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
collaborator

START Shanghai

UNKNOWN

collaborator

Beijing Bozhiyin T&S Co., Ltd.

INDUSTRY

lead

OrienGene Biotechnology Ltd.

INDUSTRY

NCT01935453 - A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | Biotech Hunter | Biotech Hunter